MICRO-HOPE

MICRO-HOPE

Microalbuminuria, Cardiovascular and Renal Outcomes—Heart Outcomes Prevention Evaluation. A HOPE substudy which found that ramipril reduces macro- and microvascular complications of hypertensive patients with diabetes. MICRO-HOPE concluded that the ramipril-treated group had a 22% to 37% reduction in progression to overt nephropathy, acute MI, stroke, and cardiovascular death.

MICRO-HOPE

Cardiology A HOPE substudy–Microalbuminuria, Cardiovascular & Renal Outcomes–Heart Outcomes Prevention Evaluation–that found that ramipril prevents macro- and microvascular complications of hypertensive Pts with DM. See HOPE.
Mentioned in ?
References in periodicals archive ?
Na mesma epoca, os resultados do classico estudo MICRO-HOPE (24) reforcaram essa evidencia, utilizando um diferente IECA, o ramipril, demonstrando capacidade de prevenir a evolucao de micro para macroalbuminuria no DM2, com reducao da nefropatia manifesta em 24%; p = 0,027.
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy.
Previously unpublished results of MICRO-HOPE (Microalbuminuria, Cardiovascular, and Renal Outcomes in the Heart Outcomes Prevention Evaluation), a prospective substudy within the landmark HOPE study, failed to show any benefit for 400 IU of vitamin E per day over placebo for the prevention of microvascular complications in 3,654 randomized patients with diabetes mellitus.
Vitamin E also failed to have any impact on cardiovascular events in diabetic participants in MICRO-HOPE or in nondiabetic subjects with cardiovascular disease who were randomized to receive vitamin E in the larger HOPE trial.
Vitamin E was studied in HOPE and MICRO-HOPE because results of the Physicians' Health Study, the Nurses' Health Study, and other observational studies suggested that ingesting more than 100 IU of vitamin E per day reduces the risk of cardiovascular disease.
MICRO-HOPE, a subset of the HOPE trial, studied ramipril (Altace) 10 mg/d vs placebo in 2437 patients with diabetes who did not have clinical proteinuria.
8] The Heart Outcomes Prevention Evaluation (HOPE) study and the MICRO-HOPE substudy added a low dose of ramipril to the current regimen in patients with diabetes who are older than 55 years and have additional risk factors,[8] which lowered the risk of death, cardiovascular events, and nephropathy by 24% to 25% each.